South China Children's Leukemia Group
Quick facts
Marketed products
- 6MP · Oncology
6MP (6-mercaptopurine) is a purine analog that inhibits nucleotide synthesis and DNA replication, leading to cell death in rapidly dividing cells. - ATO · Oncology
Arsenic trioxide induces differentiation and apoptosis of leukemic cells, particularly in acute promyelocytic leukemia. - ATRA · Oncology
ATRA (all-trans retinoic acid) promotes differentiation of acute promyelocytic leukemia cells and induces apoptosis by binding to retinoic acid receptors. - MTX · Oncology
MTX (methotrexate) inhibits dihydrofolate reductase, blocking the synthesis of purines and pyrimidines required for DNA replication and cell division. - RIF · Oncology (supportive care) / Infectious Disease
RIF is a rifampicin-based antimicrobial agent used in pediatric leukemia supportive care to prevent or treat infections.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- South China Children's Leukemia Group portfolio CI brief
- South China Children's Leukemia Group pipeline updates RSS
Frequently asked questions about South China Children's Leukemia Group
What are South China Children's Leukemia Group's marketed drugs?
Top marketed products include 6MP, ATO, ATRA, MTX, RIF.